Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
30 results
D3.181 - Oral Immunotherapy for food allergy through a personalised approach
D3.182 - Initiating Sublingual Immunotherapy in Pre-Adolescence (
D3.193 - Dual Blockade of TSLP and IL11 with a bispecific antibody: A Promising Strategy for the Treatment of Asthma and Other Airway Disorders
D3.194 - Carry-Over Effect of House Dust Mite (HDM) Immunotherapy for Allergic Respiratory Conditions in Pediatric and Adolescent Populations: A Systematic Review and Narrative Synthesis
D3.189 - Oral Immunotherapy–Associated Eosinophilic Esophagitis: A Pediatric Case Report
D3.183 - Determination of IgE antibodies against recombinant allergens (Phl p 1 and Phl p 5) in a random sample of patients from Madrid with pollinosis before and after one year of subcutaneous immunotherapy
D3.184 - Comparative immunogenicity of mixed versus individual extracts from the storage mites Acarus siro and Tyrophagus putrescentiae
D3.185 - Clinical Characteristics of Patients with Hymenoptera Venom Allergy Treated with Venom Immunotherapy: A Retrospective Study
D3.187 - Sustained Clinical Benefit of Allergen Immunotherapy in Allergic Rhinitis: A Real-Life Study
D3.188 - Real-Life Effectiveness of Subcutaneous Allergen Immunotherapy Assessed by Medication Consumption: A Retrospective Cohort Study
D3.190 - Protocol for a real-world Study to Track Response to Oralair in Naïve patients with Grass pollen allergy (STRONG) in the Netherlands
D3.191 - Demonstrating the Stability of Allergoids, the Next Generation of Allergen Therapy
D3.192 - Safety of AIT with Depigmented-polymerized extracts in patients with severe allergic asthma. A subanalysis of the SAGITAL study
D3.195 - Building expert consensus on the positioning of allergen immunotherapy (AIT) within a treatment paradigm for allergic rhinitis/rhinoconjunctivitis led by disease remission: A Delphi consensus
D3.196 - Safety of subcutaneous immunotherapy with purified native protein Cup a 1, a major allergen of Cupressus arizonica: 6-year real-world data
D3.232 - The AhR agonist tapinarof suppresses human skin inflammation by inducing metabolic reprogramming and reducing production of mitochondrial pro-inflammatory DAMPs
D3.231 - Gut Microbiome Dysbiosis in Antihistamine-Refractory Chronic Spontaneous Urticaria and Its Association with Disease Characteristics- A Cross-Sectional Case–Control Analysis
D3.233 - Polypharmacy-Associated Lichenoid Eruption Simulating Keratosis Lichenoides Chronica
D3.234 - Successful Use of Ritlecitinib in Long-Standing Alopecia Areata with Previous JAK Inhibitor Failure
D3.235 - Trends in Sensitization to Preservatives and Epoxy Resins among occupationally exposed workers: A 31-Year Patch Test analysis from Tunisia
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download